Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best healthcare stocks to buy for 2026. Takeda Pharmaceutical Company Limited (NYSE:TAK) reported Q3 FY2025 results on January 29, 2026, with revenue down 3.3% year-over-year at constant exchange rates due to VYVANSE’s loss of exclusivity. Growth and launch products rose 6.7% at CER and now account for 52% of revenue, helping offset declines. Key drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), underscoring how new products are cushioning the impact of VYVANSE’s 45.7% drop.

Financially, Takeda posted Q3 YTD revenue of ¥3,411.2 billion, core operating profit down 3.4% to ¥971.6 billion, and reported operating profit up 1.2% to ¥422.4 billion. Cash flow remained strong, with operating cash flow up 15.8% to ¥966.9 billion and adjusted free cash flow up 10.1% to ¥625.9 billion. Looking ahead, the company is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, while accelerating late-stage programs in gastrointestinal, neuroscience, and oncology to drive long-term growth.

On January 22, Takeda announced the U.S. launch of GAMMAGARD LIQUID ERC, a ready-to-use immunoglobulin therapy for primary immunodeficiency (PI) patients aged two and older. The 10% solution, with IgA content ≤2 μg/mL, can be administered intravenously or subcutaneously without reconstitution, easing treatment for patients and providers. Available in 5g/50mL and 10g/100mL vials, it features Enhanced Removal Capability to lower IgA levels, offers long shelf life at room temperature or refrigeration, and adds to Takeda’s broad IG portfolio. While not specifically indicated for IgA sensitivity, it may suit some PI patients, though risks such as thrombosis, renal dysfunction, and hypersensitivity remain.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a top-20 global, R&D-driven biopharmaceutical company headquartered in Japan, focusing on discovering, developing, and manufacturing innovative medicines. Key areas include oncology, rare diseases, neuroscience, gastroenterology (GI), plasma-derived therapies, and vaccines.

While we acknowledge the potential of TAK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.